Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07358078 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Study acronym: DemonsTTRate
StatusRecruiting
PhaseNot specified
Started2026-01-09
View on ClinicalTrials.gov ↗

Amendment history

2026-09-04
Study Status, Study Description, Contacts/Locations v3
Trial sites expanded: 4 → 24 locations
2026-04-23
Study Status, Contacts/Locations v2
Study sites3→4
2026-03-30
Study Status, Contacts/Locations v1
Study sites1→3
2026-01-13
Original filing
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Trial Details
NCT Number NCT07358078
Lead Sponsor Alnylam Pharmaceuticals
Conditions Transthyretin Amyloidosis With Cardiomyopathy
Enrollment 2,000 participants
Start Date 2026-01-09
Primary Completion 2030-10-23 (estimated)
Study Completion 2030-10-23 (estimated)
Updated on ClinicalTrials.gov 2026-09-09